| Date:                         | March 5,2023  |
|-------------------------------|---|
| Your Name:                    | Xiaonan Yang  |
| Manuscript Title:             | Real-world management of abnormal scarring using topical silicone gel: Expert consensus and case series from the Asian SCARS Expert Group |
| Manuscript Number (if known): | Click or tap here to enter text.  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   |  | e all entities with whom you have this<br>ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments wer<br>made to you or to your institution) | re |
|---|---|--|---|---|----|
|   |   | Time frame: Since the initial planning of the work |   |   |    |
| 1 | All support for the<br>present<br>manuscript (e.g.,<br>funding, provision<br>of study materials,<br>medical writing,<br>article processing<br>charges, etc.)<br>No time limit for<br>this item. |  | None  | Click the tab key to add additional rows.   |    |
|   |   |  | Time frame: past 36 month   | S   |    |
| 2 | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).  |  | None  |   |    |
| 3 | Royalties or<br>licenses  |  | None  |   | ]  |

|    |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|--|---|
| 4  | Consulting fees   | □ None X   |   |
| 5  | Payment or<br>honoraria for<br>lectures,<br>presentations,<br>speakers<br>bureaus,<br>manuscript<br>writing or<br>educational<br>events | None X   |   |
| 6  | Payment for<br>expert testimony   | □ None X   |   |
| 7  | Support for<br>attending<br>meetings and/or<br>travel   | □ None<br>X<br>□ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □   |   |
| 8  | Patents planned,<br>issued or pending   | □ None X   |   |
| 9  | Participation on a<br>Data Safety<br>Monitoring Board<br>or Advisory Board  | □ None<br>X<br>□   |   |
| 10 | Leadership or<br>fiduciary role in<br>other board,<br>society,<br>committee or<br>advocacy group,<br>paid or unpaid                     | □ None X   |   |

|      |  | Name all entities with whom you have this relationship or indicate none (add rows as |  | ts were |
|------|--|--|--|---------|
| 11   | Stock or stock<br>options  | □ None X   |  |         |
| 12   | Receipt of<br>equipment,<br>materials, drugs,<br>medical writing,<br>gifts or other<br>services  | □ None<br>X  |  |         |
| 13   | Other financial or<br>non-financial<br>interests   | □ None<br>x  |  |         |
| Plea | Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form. |  |  |         |

| Date:                         | 3/29/2023   |
|-------------------------------|---|
| Your Name:                    | Visnu Lohsiriwat  |
| Manuscript Title:             | Real-world management of abnormal scarring using topical silicone gel: Expert consensus and case series from the Asian SCARS Expert Group |
| Manuscript Number (if known): | Click or tap here to enter text.  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   |  | e all entities with whom you have this<br>ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|---|
|   |   | Time frame: Since the initial planning of the work |   |   |
| 2 | All support for the<br>present<br>manuscript (e.g.,<br>funding, provision<br>of study materials,<br>medical writing,<br>article processing<br>charges, etc.)<br><b>No time limit for</b><br><b>this item.</b><br>Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above). |  | None Time frame: past 36 month None   | Click the tab key to add additional rows.   |
| 3 | Royalties or<br>licenses  |  | None  |   |

|    |   | Name all entities with whom you have thisSpecifications/Comments (e.g., if paymentsrelationship or indicate none (add rows as needed)made to you or to your institution) | s were |
|----|---|--|--------|
| 4  | Consulting fees   | None   |        |
| 5  | Payment or<br>honoraria for<br>lectures,<br>presentations,<br>speakers<br>bureaus,<br>manuscript<br>writing or<br>educational<br>events | None   |        |
| 6  | Payment for<br>expert testimony   | ☑       None         □       □         □       □         □       □   |        |
| 7  | Support for<br>attending<br>meetings and/or<br>travel   | None   |        |
| 8  | Patents planned,<br>issued or<br>pending  | ☑         None   |        |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board   | ☑         None           □         □           □         □           □         □   |        |
| 10 | Leadership or<br>fiduciary role in<br>other board,<br>society,<br>committee or<br>advocacy group,<br>paid or unpaid                     | None   |        |

|           |   |  | e all entities with whom you have this<br>ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----------|---|--|---|---|
| 11        | Stock or stock<br>options   |  | None  |   |
| 12        | Receipt of<br>equipment,<br>materials, drugs,<br>medical writing,<br>gifts or other<br>services |  | None  |   |
| 13        | Other financial or<br>non-financial<br>interests  |  | None  |   |
| Plea<br>⊠ | Please place an "X" next to the following statement to indicate your agreement:                 |  |   |   |

| Date:                         | 2/24/2023   |
|-------------------------------|---|
| Your Name:                    | Frank Chun-Shin, Chang  |
| Manuscript Title:             | Real-world management of abnormal scarring using topical silicone gel: Expert consensus and case series from the Asian SCARS Expert Group |
| Manuscript Number (if known): | Click or tap here to enter text.  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|                            |   |  | ons/Comments (e.g., if payments were<br>ou or to your institution) |  |
|----------------------------|---|--|--|--|
|                            |   | Time frame: Since the initial planning of the work                               |  |  |
| 1                          | All support for the<br>present<br>manuscript (e.g.,<br>funding, provision<br>of study materials,<br>medical writing,<br>article processing<br>charges, etc.)<br><b>No time limit for<br/>this item.</b> |  | ey to add additional rows.   |  |
| Time frame: past 36 months |   |  |  |  |
| 2                          | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).  | ☑ None   |  |  |
| 3                          | Royalties or<br>licenses  | ☑         None           □         □           □         □           □         □ |  |  |

|    |   | Name all entities with whom you have thisSpecifications/Comments (e.g., if paymentsrelationship or indicate none (add rows as needed)made to you or to your institution) | s were |
|----|---|--|--------|
| 4  | Consulting fees   | None   |        |
| 5  | Payment or<br>honoraria for<br>lectures,<br>presentations,<br>speakers<br>bureaus,<br>manuscript<br>writing or<br>educational<br>events | None   |        |
| 6  | Payment for<br>expert testimony   | ☑       None         □       □         □       □         □       □   |        |
| 7  | Support for<br>attending<br>meetings and/or<br>travel   | None   |        |
| 8  | Patents planned,<br>issued or<br>pending  | ☑         None   |        |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board   | ☑         None           □         □           □         □           □         □   |        |
| 10 | Leadership or<br>fiduciary role in<br>other board,<br>society,<br>committee or<br>advocacy group,<br>paid or unpaid                     | None   |        |

|           |   |  | e all entities with whom you have this<br>ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----------|---|--|---|---|
| 11        | Stock or stock<br>options   |  | None  |   |
| 12        | Receipt of<br>equipment,<br>materials, drugs,<br>medical writing,<br>gifts or other<br>services |  | None  |   |
| 13        | Other financial or<br>non-financial<br>interests  |  | None  |   |
| Plea<br>⊠ | Please place an "X" next to the following statement to indicate your agreement:                 |  |   |   |

| Date:                         | 3/23/2023  |  |
|-------------------------------|--|--|
| Your Name:                    | Dr Tan Thiam Chye  |  |
| Manuscript Title:             | Real-world management of abnormal scarring using topical silicone gel: Expert consensus and<br>case series from the Asian SCARS Expert Group |  |
| Manuscript Number (if known): | ΝΑ   |  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)   | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial planning   | ; of the work   |
| 1 | All support for the<br>present<br>manuscript (e.g.,<br>funding, provision<br>of study materials,<br>medical writing,<br>article processing<br>charges, etc.)<br><b>No time limit for<br/>this item.</b> | ☑ None          Image: Second secon | Click the tab key to add additional rows.   |
| 2 | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).  | None   |   |
| 3 | Royalties or<br>licenses  | ⊠ None   |   |

|    |   | e all entities with whom you have this<br>onship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|--|---|
| 4  | Consulting fees   | None   |   |
| 5  | Payment or<br>honoraria for<br>lectures,<br>presentations,<br>speakers<br>bureaus,<br>manuscript<br>writing or<br>educational<br>events | None Honararium for expert discussion  |   |
| 6  | Payment for<br>expert testimony   | None   |   |
| 7  | Support for<br>attending<br>meetings and/or<br>travel   | None   |   |
| 8  | Patents planned,<br>issued or<br>pending  | None   |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board   | None   |   |
| 10 | Leadership or<br>fiduciary role in<br>other board,<br>society,<br>committee or<br>advocacy group,<br>paid or unpaid                     | None   |   |

|           |   |  | e all entities with whom you have this<br>ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----------|---|--|---|---|
| 11        | Stock or stock<br>options   |  | None  |   |
| 12        | Receipt of<br>equipment,<br>materials, drugs,<br>medical writing,<br>gifts or other<br>services |  | None  |   |
| 13        | Other financial or<br>non-financial<br>interests  |  | None  |   |
| Plea<br>× | Please place an "X" next to the following statement to indicate your agreement:                 |  |   |   |

| Date:                         | 3/20/2023   |
|-------------------------------|---|
| Your Name:                    | Catherine J. Howard   |
| Manuscript Title:             | Real-world management of abnormal scarring using topical silicone gel: Expert consensus and _ case series from the Asian SCARS Expert Group |
| Manuscript Number (if known): | Click or tap here to enter text.  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial planning   | of the work   |
|   | All support for the<br>present<br>manuscript (e.g.,<br>funding, provision<br>of study materials,<br>medical writing,<br>article processing<br>charges, etc.)<br><b>No time limit for<br/>this item.</b> | None   | Click the tab key to add additional rows.   |
| 2 | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).  | None   |   |
| 3 | Royalties or<br>licenses  | None   |   |

|    |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)  | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|---|---|
| 4  | Consulting fees   | ⊠         None  |   |
| 5  | Payment or<br>honoraria for<br>lectures,<br>presentations,<br>speakers<br>bureaus,<br>manuscript<br>writing or<br>educational<br>events | <ul> <li>None</li> <li>Biofemme Unilab</li> <li>Philippine Family Physician</li> <li>Bayer</li> <li>Cardinal Santo Medical Center</li> <li>Quezon City Medical Society</li> </ul> |   |
| 6  | Payment for<br>expert testimony   | ⊠ None  |   |
| 7  | Support for<br>attending<br>meetings and/or<br>travel   | None           Cathay Drug Philippines           Biofemme Unilab  |   |
| 8  | Patents planned,<br>issued or<br>pending  | ⊠ None  |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board   | None  |   |
| 10 | Leadership or<br>fiduciary role in<br>other board,<br>society,<br>committee or<br>advocacy group,<br>paid or unpaid                     | None     Cardinal Santos Medical Center   |   |

|           |   |  | e all entities with whom you have this<br>ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----------|---|--|---|---|
| 11        | Stock or stock<br>options   |  | None  |   |
| 12        | Receipt of<br>equipment,<br>materials, drugs,<br>medical writing,<br>gifts or other<br>services |  | None  |   |
| 13        | Other financial or<br>non-financial<br>interests  |  | None  |   |
| Plea<br>× | Please place an "X" next to the following statement to indicate your agreement:                 |  |   |   |

| Date:                         | 2/22/2023   |
|-------------------------------|---|
| Your Name:                    | Liang Qiao  |
| Manuscript Title:             | Real-world management of abnormal scarring using topical silicone gel: Expert consensus and case series from the Asian SCARS Expert Group |
| Manuscript Number (if known): | Click or tap here to enter text.  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)   | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial planning   | of the work   |
| 1 | All support for the<br>present<br>manuscript (e.g.,<br>funding, provision<br>of study materials,<br>medical writing,<br>article processing<br>charges, etc.)<br>No time limit for<br>this item. | ☑ None          Image: Second secon | Click the tab key to add additional rows.   |
| 2 | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).  | None   |   |
| 3 | Royalties or<br>licenses  | None   |   |

|    |   | Name all entities with whom you have thisSpecifications/Comments (e.g., if paymentsrelationship or indicate none (add rows as needed)made to you or to your institution) | s were |
|----|---|--|--------|
| 4  | Consulting fees   | None   |        |
| 5  | Payment or<br>honoraria for<br>lectures,<br>presentations,<br>speakers<br>bureaus,<br>manuscript<br>writing or<br>educational<br>events | None   |        |
| 6  | Payment for<br>expert testimony   | ☑       None         □       □         □       □         □       □   |        |
| 7  | Support for<br>attending<br>meetings and/or<br>travel   | None   |        |
| 8  | Patents planned,<br>issued or<br>pending  | ☑         None   |        |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board   | ☑         None           □         □           □         □           □         □   |        |
| 10 | Leadership or<br>fiduciary role in<br>other board,<br>society,<br>committee or<br>advocacy group,<br>paid or unpaid                     | None   |        |

|   |   |  | e all entities with whom you have this<br>ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|---|
| 11  | Stock or stock<br>options   |  | None  |   |
| 12  | Receipt of<br>equipment,<br>materials, drugs,<br>medical writing,<br>gifts or other<br>services |  | None  |   |
| 13  | Other financial or<br>non-financial<br>interests  |  | None  |   |
| Please place an "X" next to the following statement to indicate your agreement: |   |  |   |   |

| Date:                         | 3/7/2023  |
|-------------------------------|---|
| Your Name:                    | Sheng-Wen Steven Shaw   |
| Manuscript Title:             | Real-world management of abnormal scarring using topical silicone gel: Expert consensus and case series from the Asian SCARS Expert Group |
| Manuscript Number (if known): | Click or tap here to enter text.  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|          |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----------|--|--|---|
|          |  | Time frame: Since the initial planning o   | of the work   |
| <b>1</b> | All support for the<br>present<br>manuscript (e.g.,<br>funding, provision  | ₩ None   |   |
|          | of study materials,<br>medical writing,<br>article processing<br>charges, etc.)<br>No time limit for<br>this item. |  | Click the tab key to add additional rows.   |
|          |  | Time frame: past 36 months   | s   |
| 2        | Grants or<br>contracts from  | V None   |   |
|          | any entity (if not<br>indicated in item<br>#1 above).  |  |   |
| 3        | Royalties or<br>licenses   | None   |   |
|          |  |  |   |
|          |  |  |   |

8/26/2021

| 4       Consulting fees       ✓       None         5       Payment or honoraria for lectures, presentations, speakers bureaus, speakers bureaus, events       ✓       None         -       manuscript writing or educational revents       ✓       ✓       ✓   | ion) |
|--|------|
| honoraria for<br>lectures,<br>presentations,<br>speakers<br>bureaus,<br>manuscript<br>writing or<br>educational.   |      |
|  |      |
| 6       Payment for expert testimony         Image: state of the stat |      |
| 7     Support for attending meetings and/or travel   |      |
| 8 Patents planned, issued or pending   |      |
| 9       Participation on a Data Safety         Monitoring Board of Advisory Board  |      |
| 10       Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid       None         50       Image: Committee or                    |      |

8/26/2021

2

ICMJE Disclosure Form

!

. . . . . . . . . .

|           |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----------|--|--|---|
| 11        | Stock or stock options   | ₩ None   |   |
|           |  |  |   |
|           | and a second |  |   |
| <u>12</u> | Receipt of<br>equipment,<br>materials, drugs,<br>medical writing,  | ₩ None   |   |
|           | gifts or other<br>services   |  |   |
| 13        | Other financial or<br>non-financial<br>interests   | ₩ None   |   |
|           |  |  |   |
| Plea      | ise place an "X" next  | t to the following statement to indicate your agreemer                                       | n: S. Shaw  |
| X         | l certify that I have  | answered every question and have not altered the wor   | ding of any of the questions on this form.  |

••

| Date:                         | 3/6/2023   |  |
|-------------------------------|--|--|
| Your Name:                    | Tran Nguyen Anh Tu   |  |
| Manuscript Title:             | Improved traumatic scar with the combined use of silicone gel and laser therapy] |  |
| Manuscript Number (if known): | Click or tap here to enter text.   |  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial planning   | of the work   |
| 1 | All support for the<br>present<br>manuscript (e.g.,<br>funding, provision<br>of study materials,<br>medical writing,<br>article processing<br>charges, etc.)<br>No time limit for<br>this item. | None   | Click the tab key to add additional rows.   |
|   |   | Time frame: past 36 month  | IS  |
| 2 | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).  | None   |   |
| 3 | Royalties or<br>licenses  | None   |   |

|    |   | Name all entities with whom you have thisSpecifications/Comments (e.g., if paymentrelationship or indicate none (add rows as needed)made to you or to your institution) | s were |
|----|---|---|--------|
| 4  | Consulting fees   | None  |        |
| 5  | Payment or<br>honoraria for<br>lectures,<br>presentations,<br>speakers<br>bureaus,<br>manuscript<br>writing or<br>educational<br>events | None  |        |
| 6  | Payment for<br>expert testimony   | None  |        |
| 7  | Support for<br>attending<br>meetings and/or<br>travel   | None  |        |
| 8  | Patents planned,<br>issued or<br>pending  | ☑         None  |        |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board   | ☑       None         ☑       ☑         ☑       ☑         ☑       ☑         ☑       ☑  |        |
| 10 | Leadership or<br>fiduciary role in<br>other board,<br>society,<br>committee or<br>advocacy group,<br>paid or unpaid                     | None  |        |

|           |   |  | e all entities with whom you have this<br>ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----------|---|--|---|---|
| 11        | Stock or stock<br>options   |  | None  |   |
| 12        | Receipt of<br>equipment,<br>materials, drugs,<br>medical writing,<br>gifts or other<br>services |  | None  |   |
| 13        | Other financial or<br>non-financial<br>interests  |  | None  |   |
| Plea<br>× | Please place an "X" next to the following statement to indicate your agreement:                 |  |   |   |

| Date:                         | 3/6/2023  |
|-------------------------------|---|
| Your Name:                    | CHAN Yung   |
| Manuscript Title:             | Real-world management of abnormal scarring using topical silicone gel: Expert consensus and case series from the Asian SCARS Expert Group |
| Manuscript Number (if known): | Click or tap here to enter text.  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution)          |
|---|---|--|--|
|   | Time frame: Since the initial planning of the work  |  |  |
| 1 | All support for the<br>present<br>manuscript (e.g.,<br>funding, provision<br>of study materials,<br>medical writing,<br>article processing<br>charges, etc.)<br><b>No time limit for<br/>this item.</b> |  | Received honorarium for participating the study<br>Click the tab key to add additional rows. |
| 2 | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).  | ☑ None   |  |
| 3 | Royalties or<br>licenses  | None   |  |

|    |   | Name all entities with whom you have thisSpecifications/Comments (e.g., if paymentsrelationship or indicate none (add rows as needed)made to you or to your institution) | were |
|----|---|--|------|
| 4  | Consulting fees   | ☑         None           □         □           □         □           □         □           □         □   |      |
| 5  | Payment or<br>honoraria for<br>lectures,<br>presentations,<br>speakers<br>bureaus,<br>manuscript<br>writing or<br>educational<br>events | None   |      |
| 6  | Payment for<br>expert testimony   | ☑       None         □       □         □       □         □       □         □       □   |      |
| 7  | Support for<br>attending<br>meetings and/or<br>travel   | ☑       None         □       □         □       □         □       □         □       □   |      |
| 8  | Patents planned,<br>issued or<br>pending  | None   |      |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board   | None   |      |
| 10 | Leadership or<br>fiduciary role in<br>other board,<br>society,<br>committee or<br>advocacy group,<br>paid or unpaid                     | None   |      |

|           |   |  | e all entities with whom you have this<br>ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----------|---|--|---|---|
| 11        | Stock or stock<br>options   |  | None  |   |
| 12        | Receipt of<br>equipment,<br>materials, drugs,<br>medical writing,<br>gifts or other<br>services |  | None  |   |
| 13        | Other financial or<br>non-financial<br>interests  |  | None  |   |
| Plea<br>⊠ | Please place an "X" next to the following statement to indicate your agreement:                 |  |   |   |

| Date:                         | 4/24/2023   |  |
|-------------------------------|---|--|
| Your Name:                    | Daniel Dellosa  |  |
| Manuscript Title:             | Real-world management of abnormal scarring using topical silicone gel: Expert consensus and case series from the Asian SCARS Expert Group |  |
| Manuscript Number (if known): | Click or tap here to enter text.  |  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial planning   | of the work   |
| 1 | All support for the<br>present<br>manuscript (e.g.,<br>funding, provision<br>of study materials,<br>medical writing,<br>article processing<br>charges, etc.)<br><b>No time limit for<br/>this item.</b> | None     Employee of A.Menarini Pte Ltd  | Click the tab key to add additional rows.   |
|   |   | Time frame: past 36 month  | S   |
| 2 | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).  | None   |   |
| 3 | Royalties or<br>licenses  | None   |   |

|    |   | Name all entities with whom you have thisSpecifications/Comments (e.g., if paymentrelationship or indicate none (add rows as needed)made to you or to your institution) | ts were |
|----|---|---|---------|
| 4  | Consulting fees   | None  |         |
| 5  | Payment or<br>honoraria for<br>lectures,<br>presentations,<br>speakers<br>bureaus,<br>manuscript<br>writing or<br>educational<br>events | None  |         |
| 6  | Payment for<br>expert testimony   | ☑       None         □       □         □       □         □       □         □       □  |         |
| 7  | Support for<br>attending<br>meetings and/or<br>travel   | None  |         |
| 8  | Patents planned,<br>issued or<br>pending  | ☑         None           □         □           □         □  |         |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board   | ☑         None  |         |
| 10 | Leadership or<br>fiduciary role in<br>other board,<br>society,<br>committee or<br>advocacy group,<br>paid or unpaid                     | None  |         |

|   |   |  | e all entities with whom you have this<br>ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|---|
| 11  | Stock or stock<br>options   |  | None  |   |
| 12  | Receipt of<br>equipment,<br>materials, drugs,<br>medical writing,<br>gifts or other<br>services |  | None  |   |
| 13  | Other financial or<br>non-financial<br>interests  |  | None  |   |
| Please place an "X" next to the following statement to indicate your agreement: |   |  |   |   |

| Date:                         | 4/24/2023   |  |
|-------------------------------|---|--|
| Your Name:                    | Dinesh Nagrale  |  |
| Manuscript Title:             | Real-world management of abnormal scarring using topical silicone gel: Expert consensus and case series from the Asian SCARS Expert Group |  |
| Manuscript Number (if known): | Click or tap here to enter text.  |  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|  |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)  | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|--|---|---|---|
|  |   | Time frame: Since the initial planning o  | of the work   |
| <ul> <li>All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)</li> <li>No time limit for this item.</li> <li>Grants or</li> </ul> |   | □ None         Employee of A.Menarini Pte Ltd         □ | Click the tab key to add additional rows.   |
|  | contracts from<br>any entity (if not<br>indicated in item<br>#1 above). |   |   |
| 3  | Royalties or<br>licenses  | None  |   |

|    |   | Name all entities with whom you have thisSpecifications/Comments (e.g., if paymentrelationship or indicate none (add rows as needed)made to you or to your institution) | ts were |
|----|---|---|---------|
| 4  | Consulting fees   | None  |         |
| 5  | Payment or<br>honoraria for<br>lectures,<br>presentations,<br>speakers<br>bureaus,<br>manuscript<br>writing or<br>educational<br>events | None  |         |
| 6  | Payment for<br>expert testimony   | ☑       None         □       □         □       □         □       □  |         |
| 7  | Support for<br>attending<br>meetings and/or<br>travel   | None  |         |
| 8  | Patents planned,<br>issued or<br>pending  | ☑         None           □         □           □         □  |         |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board   | ☑         None  |         |
| 10 | Leadership or<br>fiduciary role in<br>other board,<br>society,<br>committee or<br>advocacy group,<br>paid or unpaid                     | None  |         |

|   |   |  | e all entities with whom you have this<br>ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|---|
| 11  | Stock or stock<br>options   |  | None  |   |
| 12  | Receipt of<br>equipment,<br>materials, drugs,<br>medical writing,<br>gifts or other<br>services |  | None  |   |
| 13  | Other financial or<br>non-financial<br>interests  |  | None  |   |
| Please place an "X" next to the following statement to indicate your agreement: |   |  |   |   |